| Literature DB >> 30636579 |
Sadaf Ghanaatgar-Kasbi1, Shadi Khorrami1, Amir Avan1, Seyed A Aledavoud1, Gordon A Ferns2.
Abstract
The c-mesenchymal-epithelial transition factor (c-MET) is involved in the tumorigenesis of various cancers. HGF/Met inhibitors are now attracting considerable interest due to their anti-tumor activity in multiple malignancies such as pancreatic cancer. It is likely that within the next few years, HGF/Met inhibitors will become a crucial component for cancer management. In this review, we summarize the role of HGF/Met pathway in the pathogenesis of pancreatic cancer, with particular emphasize on HGF/Met inhibitors in the clinical setting, including Cabozantinib (XL184, BMS-907351), Crizotinib (PF-02341066), MK-2461, Merestinib (LY2801653), Tivantinib (ARQ197), SU11274, Onartuzumab (MetMab), Emibetuzumab (LY2875358), Ficlatuzumab (AV- 299), Rilotumumab (AMG 102), and NK4 in pancreatic cancer. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.Entities:
Keywords: HGF/Met inhibitors; anti-tumor activity; c-mesenchymal-epithelial transition factor; pancreatic cancer; tumorigenesis.
Mesh：
Substances：
Year: 2018 PMID： 30636579 DOI： 10.2174/1381612825666190110145855
Source DB: PubMed Journal: Curr Pharm Des ISSN： 1381-6128 Impact factor: 3.116